Blood Pressure Drug Candesartan Cilexetil Shows Promise Against MRSA Infections in Laboratory Study
Key Insights
A new study published in Nature Communications found that candesartan cilexetil, a commonly used blood pressure medication, can disrupt MRSA (search) bacterial cell membranes and interfere with essential cellular functions.
Laboratory experiments demonstrated the drug's effectiveness across different bacterial growth stages and its ability to significantly reduce biofilm (search) formation, which typically makes infections more resistant to treatment.
The research represents a promising drug repurposing approach that could accelerate treatment development for antibiotic-resistant infections (search) without the lengthy timelines associated with creating entirely new medications.
A commonly prescribed blood pressure medication has demonstrated unexpected potential as a weapon against one of medicine's most challenging adversaries: methicillin-resistant Staphylococcus aureus (MRSA (search)). Research published in Nature Communications reveals that candesartan cilexetil can effectively disrupt MRSA bacterial membranes and reduce biofilm (search) formation in laboratory studies, offering a promising new approach to combat antibiotic-resistant infections (search).
The study, led by Dr. Eleftherios Mylonakis, Chair of the Houston Methodist (search) Charles W. Duncan Jr. Department of Medicine, addresses a critical global health challenge. Antibiotic-resistant infections (search) cause over 2.8 million infections and more than 35,000 deaths annually in the United States alone, with MRSA (search) representing one of the most dangerous and difficult-to-treat pathogens.
Targeting Bacterial Defenses Through Drug Repurposing
Rather than developing new antibiotics from scratch—a process that is both expensive and time-consuming—the research team investigated whether existing medications could be repurposed to fight bacterial infections. The scientists focused on disrupting bacterial cell membranes, the protective outer layers that help bacteria survive and resist treatment.
Nagendran Tharmalingam and his team discovered that candesartan cilexetil can effectively target MRSA (search) by disrupting the bacterial cell membrane (search) and interfering with essential cellular functions. This membrane disruption weakens the bacteria and makes them more susceptible to destruction.
Broad-Spectrum Effectiveness Against MRSA
The laboratory experiments revealed several promising characteristics of the blood pressure drug's antibacterial activity. The medication proved effective at killing MRSA (search) across different stages of bacterial growth, an important finding since bacteria behave differently depending on whether they are actively growing or in a more stable state. Many existing treatments only work during specific growth phases, making this broad-spectrum activity particularly valuable.
Perhaps most significantly, the drug demonstrated the ability to reduce biofilm (search) formation. Biofilms are clusters of bacteria that stick together and form protective layers, making them much harder to treat with conventional antibiotics. By inhibiting biofilm formation, candesartan cilexetil could help make MRSA (search) infections easier to control and treat.
Advantages of Drug Repurposing Strategy
The research highlights several advantages of repurposing existing medications for new therapeutic applications. Candesartan cilexetil has already been extensively tested for safety in humans for its original blood pressure-lowering purpose, potentially accelerating the development process for its new antibacterial application compared to creating entirely new drugs.
This approach could provide a more cost-effective and faster pathway to expanding treatment options for antibiotic-resistant infections (search). The drug's established safety profile and widespread clinical use make it an attractive candidate for further development as an antimicrobial agent.
Future Research Directions
While the laboratory findings are encouraging, important steps remain before this treatment approach can be implemented in clinical practice. The study was conducted entirely in laboratory settings, and researchers acknowledge that real-life infections present greater complexity than controlled laboratory conditions.
Future research will need to evaluate how the drug performs in the human body, including whether it can reach infected areas at therapeutic levels and maintain its effectiveness against different MRSA (search) strains. Scientists will also need to determine optimal dosing strategies and assess potential interactions with other medications.
The research represents a significant step forward in addressing the growing global problem of antibiotic resistance through innovative approaches that leverage existing pharmaceutical resources rather than relying solely on the development of new drugs.